A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer

Yong Wang; Rong Chen; Jing Zhang; Peng Zeng

doi:10.1371/journal.pone.0299949

. 2024 Apr 18;19(4):e0299949. doi: 10.1371/journal.pone.0299949

A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer

Yong Wang ¹, Rong Chen ², Jing Zhang ², Peng Zeng ^2,^*

Editor: Arthur J Lustig³

PMCID: PMC11025932 PMID: 38635758

Abstract

Background

Although there is evidence that ribonucleotide reductase subunit M2 (RRM2) is associated with numerous cancers, pan-cancer analysis has seldom been conducted. This study aimed to explore the potential carcinogenesis of RRM2 in pan-cancer using datasets from The Cancer Genome Atlas (TCGA).

Methods

Data from the UCSC Xena database were analyzed to investigate the differential expression of RRM2 across multiple cancer types. Clinical data such as age, race, sex, tumor stage, and status were acquired to analyze the influence of RRM2 on the clinical characteristics of the patients. The role of RRM2 in the onset and progression of multiple cancers has been examined in terms of genetic changes at the molecular level, including tumor mutational burden (TMB), microsatellite instability (MSI), biological pathway changes, and the immune microenvironment.

Results

RRM2 was highly expressed in most cancers, and there was an obvious correlation between RRM2 expression and patient prognosis. RRM2 expression is associated with the infiltration of diverse immune and endothelial cells, immune checkpoints, tumor mutational burden (TMB), and microsatellite instability (MSI). Moreover, the cell cycle is involved in the functional mechanisms of RRM2.

Conclusions

Our pan-cancer study provides a comprehensive understanding of the carcinogenesis of RRM2 in various tumors.

Introduction

Given the complex causes of tumorigenesis such as genetic loss or alteration [1] and immune infiltration [2], it is crucial to perform pan-cancer analyses of genes that may have potential clinical value. Recently, with deeper research examining the initiation, development, and treatment of tumors, many therapeutic concepts have emerged, including immune checkpoint proteins [3] and immune infiltration [4]. Interestingly, the publicly funded TGCA project and many powerful bioinformatics tools have allowed us to perform pan-cancer analyses.

Ribonucleotide reductase subunit M2 (RRM2), a subunit of ribonucleotide reductase, supports DNA synthesis and repair by catalyzing the formation of deoxyribonucleotides (dNTP) [5]. RRM2 governs nucleotide metabolism in tumor cells [6] and is associated with multiple cancers [7, 8]. Several studies have demonstrated that RRM2 is a potential diagnostic or prognostic biomarker for Ewing sarcoma [9], liver cancer [10], glioma [11], and lung adenocarcinoma [12]. Moreover, RRM2 is an important target of many factors and drugs that suppress tumorigenicity in various cancers [13–16]. For example, DHS (trans-4,4’-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 expression in pancreatic, ovarian, and colorectal cancer [17].

Although the oncogenic role of RRM2 has been elucidated in several tumors, there is no pan-cancer evidence regarding the relationship between RRM2 and various cancer types based on big clinical data. In this study, we performed a pan-cancer analysis of RRM2. We also explored the molecular mechanisms of RRM2 in the context of different cancers using a series of factors, including gene expression, clinical correlation, survival analysis, genetic alterations, immune infiltration, immune checkpoints, enrichment analysis, and potential drug prediction.

Materials and methods

1. The expression of RRM2 in pan-cancer

To explore RRM2 expression in different cancers, Oncomine (https://www.oncomine.org/) was used with the default parameters. Additionally, we downloaded gene expression RNA-seq data of 33 cancers from The Cancer Genome Atlas (TCGA) dataset in UCSC Xena [18]. The Perl language (https://www.perl.org/) was used to extract RRM2 expression data from 33 cancer samples. R language was used for further analysis and visualization.

2. RRM2 expression and its clinical correlation in pan-cancer

To explore the correlation between RRM2 expression and the clinical characteristics of patients with tumors (tumor stage and survival outcome), we downloaded pan-cancer clinical data from the TGCA database (https://www.cancer.gov/). R language with limma (version 3.38.3) [19] was used for visualization.

3. Survival prognosis analysis and Cox regression models

Survival data for 33 cancers were downloaded from the TGCA database for survival analysis. Kaplan–Meier (KM) and Cox regression models were used to explore RRM2 potential prognostic value of in pan-cancer. To estimate the prognostic value of RRM2 comprehensively, we performed overall survival (years) (OS), disease-free interval (years) (DFI), disease-specific survival (years) (DSS), and progression-free interval (years) (PFI) analyses using R language with limma, survival (version 3.1.12), forestplot (version 1.9), and survminer packages (version 0.4.7).

4. Genetic alteration analysis

We selected the “TCGA Pan Cancer Atlas Studies” in the “quick select” section and entered “RRM2” (NC_000002.12NC_000002.12) for queries regarding the genetic alteration characteristics of RRM2 in the cBioPortal web (https://www.cbioportal.org/). In the “Cancer Types Summary” module, we obtained the alteration frequency, mutation data (the type of mutation tumors), and CNA data (copy number alteration) of RRM2 in all TGCA tumors. In the “Mutations” module, the mutated site information of RRM2 was visualized in a schematic diagram of the protein structure or the 3D structure. We used the R language with the fmsb package to explore the correlation between RRM2 expression and tumor mutations in 33 TGCA cancers downloaded from the TGCA database.

Tumor mutational burden (TMB) is a biomarker that represents the total number of mutations in a tumor [20]. Microsatellite instability (MSI) reflects the loss or gain of nucleotides from repetitive DNA tracts and is a diagnostic phenotype of many cancers [21]. We explored the correlation between RRM2 expression and TMB and also MSI in pan-cancer using Perl and R language with the fmsb package (version 0.7.0).

5. Immune infiltration analysis

We chose the “Immune” module of the TIMER2 webserver [22], and RRM2 and endothelial cells were then selected for exploring the association between immune infiltrates of endothelial cells and RRM2 expression in all TCGA. A partial Spearman’s correlation analysis was performed using the Purity Adjustment” option. We further investigated the correlation between RRM2 expression and the infiltration levels of the other 22 immune cells. The R language with ggplot2 (version 3.3.2), ggpubr, and ggExtra (version 0.9) packages was used for analysis and visualization.

6. Immune checkpoint analysis

Immune checkpoint molecules are costimulatory receptors on immune cells that regulate immune cells through an immune response [23]. In this study, we used R language with the limma, reshape2, and RColorBrewer packages to analyze the relationship between RRM2 expression and the expression levels of 47 common immune checkpoint genes in pan-cancer.

7. Enrichment analysis of RRM2-related gene

In the STRING website (https://string-db.org/), we input the protein name (“RRM2”) and organism (“Homo sapiens”) in the “Protein by name” module. Subsequently, we changed the basic settings as follows: meaning of network edges: evidence; active interaction sources: experiments; minimum required interaction score: low confidence (0.150); maximum number of interactors to demonstrate no more than 50 interactors in 1st shell. Eventually, RRM2-binding proteins that were authenticated by experiments were acquired. Cytoscape (version 3.6.1) was used for integration and visualization [24]. In the “Similar Genes” section of GEPIA2 (http://gepia2.cancer-pku.cn/), we searched RRM2-correlated targeting genes by Gene (“RRM2”), Top # (“100”) similar Genes, and all TGCA tumor and normal tissues. Meanwhile, we used the “correlation analysis” module to explore the Pearson correlation between RRM2 expression and the top 5 RRM2-correlated targeting genes in all TGCA tumor and normal tissues. The “Gene_Corr” module in TIMER2 was used to indicate the correlation between RRM2 with the top 5 RRM2-correlated targeting genes in various cancer types. Subsequently, we performed intersection analysis to compare the genes with which RRM2 binds and interacts using Jvenn [25]. Furthermore, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis for the two sets of data that were RRM2-binding and correlated through the R language with clusterProfiler, ggplot2, and enrichplot packages.

8. Potential drug prediction for pan-cancer

The KEGG gene sets as Gene Symbols were downloaded from the GESE online dataset (https://www.gsea-msigdb.org/). R language with colorspace, stringi, ggplot2, limma, and enrichplot packages was used to explore RRM2-related KEGG enrichment analyses in pan-cancer. Finally, enriched pathways were counted for further drug prediction. In the Therapeutic Target Database (http://db.idrblab.net/), we selected the “Pathway Search” section of the “Advanced Search” module [26]. Then, step1: KEGG and step2: CELL CYCLE were chosen to identify pathway-associated drugs related to RRM2 expression in pan-cancer. Only approved drugs were screened.

Results

1. The expression of RRM2 in pan-cancer

To explore the oncogenic role of human RRM2, we analyzed the expression pattern of RRM2 in different cancer types using the Oncomine database (Fig 1A). The results revealed that RRM2 expression was significantly increased in most cancer groups, including bladder, brain, breast, cervical, colorectal, esophageal, gastric, head and neck, kidney, liver, lung, lymphoma, melanoma, ovarian, pancreatic, prostate, and sarcoma cancers. However, the expression of RRM2 is decreased in leukemic cells. Furthermore, we identified the expression levels of RRM2 in 33 different tumor and non-tumor tissues based on TCGA datasets. As presented in Fig 1B, the expression levels of RRM2 were extremely different between the cancer and normal groups. The expression levels of RRM2 were significantly higher in 19 tumor tissues than they were in the corresponding normal tissues, including BLCA (Bladder Urothelial Carcinoma), BRCA (breast invasive carcinoma), CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), CHOL (cholangiocarcinoma), COAD (colon adenocarcinoma), ESCA (esophageal carcinoma), GBM (glioblastoma multiforme), HNSC (Head and Neck squamous cell carcinoma), KIRC (kidney renal clear cell carcinoma), KIRP (kidney renal papillary cell carcinoma), LIHC (liver hepatocellular carcinoma), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), PCPG (Pheochromocytoma and Paraganglioma), PRAD (prostate adenocarcinoma), READ (rectal adenocarcinoma), STAD (stomach adenocarcinoma), THCA (thyroid carcinoma), and UCEC (Uterine Corpus Endometrial Carcinoma). Overall, these results indicated that RRM2 is highly expressed in most cancers and plays a potential oncogenic role.

Fig 1 — (A) The expression level of *RRM2* in different pan-cancers as indicated in the Oncomine database. Gene rank percentile (%). (B) *RRM2* differential expression in pan-cancer in the TCGA database. *P < 0.05; **P < 0.01; ***P < 0.001.

2. RRM2 expression and clinical correlation in pan-cancer

We assessed the correlation between the expression of RRM2 and the clinical characteristics of patients with pan-cancer, including age, race, tumor stage, and status. For age, significant correlations with RRM2 expression were observed in 0–29 years group (BRCA, KIRP, LUAD, PCPG, READ, STAD, TGCT (Testicular Germ Cell Tumors)), 30–49 years group (ESCA, KIRC, LAML (Acute Myeloid Leukemia), LIHC, THYM (thymoma)), 50–70 years group (LGG (brain lower-grade glioma)), LUSC), and over 70 years group (KICH (Kidney Chromophobe), PAAD (pancreatic adenocarcinoma)) (Fig 2A–2D and S1A-S1L Fig in S1 File). As for race, RRM2 expression was significantly correlated with BRCA, KICH and KIRP in asian group, BLCA, LIHC and THYM in black group, and KIRC in white group (Fig 2E–2H and S1M-S1O Fig in S1 File). Regarding the tumor stage, RRM2 expression was significantly associated with Skin Cutaneous Melanoma (SKCM) in stage I group, BRCA, COAD, LUAD, LUSC and PAAD in stage II group, KIRP, LIHC and THCA in stage III group, adrenocortical carcinoma (ACC), KICH, KIRC and TGCT in stage IV group (Fig 2I–2L and S1P-S1X Fig in S1 File). In terms of tumor status, RRM2 expression levels were significantly correlated with COAD and OV (ovarian serous cystadenocarcinoma) in tumor free group, ACC, BLCA, KICH, KIRC, KIRP, LGG, LUAD, PAAD, PCPG, PRAD and UVM (Uveal Melanoma) in tumor group (Fig 2M–2P and S1Y-S1AG Fig in S1 File).

Fig 2 — (A-D) The clinical correlation between *RRM2* expression level and age in BRCA, ESCA KICH, and KIRC, respectively. (E-H) The clinical correlation between *RRM2* expression level and race in BLCA, BRCA, KICH, and KIRC, respectively. (I-L) The clinical correlation between *RRM2* expression level and tumor stage of patients in ACC, BRCA, COAD, and KICH, respectively. (M-P) The clinical correlation between *RRM2* expression level and tumor status of patients in ACC, BLCA, COAD, and KICH, respectively. The number above the horizontal line represents the p-value between the two groups.

3. Survival analysis

To estimate the correlation between RRM2 expression and pan-cancer prognosis, we divided the tumor cases into two groups based on high and low expression levels of RRM2. The Kaplan–Meier method was applied to analyze the overall survival (years) (OS), disease-free interval (years) (DFI), disease-specific survival (years) (DSS), and progression-free interval (years) (PFI). As presented in Fig 3A–3E and S2A-S2I Fig in S1 File, OS analysis data revealed high RRM2 expression was associated with poor prognosis for the TCGA cases of ACC (P<0.001), KICH (P = 0.015), KIRC (P<0.001), KIRP (P<0.001), LGG (P<0.001), LIHC (P = 0.005), LUAD (P<0.001), MESO (Mesothelioma) (P<0.001), PAAD (P = 0.006), PRAD (P = 0.004), SARC (Sarcoma) (P = 0.04), UCEC (P = 0.021), and UVM (P<0.001). However, low RRM2 expression was associated with poor OS in patients with THYM (P = 0.017). DSS analysis data indicated a correlation between high RRM2 expression and poor prognosis in TGCA cases of ACC (P<0.001), KICH (P = 0.001), KIRC (P<0.001), KIRP (P<0.001), LGG (P<0.001), LIHC (P = 0.028), LUAD (P = 0.004), MESO (P<0.001), PAAD (P = 0.014), PRAD (P = 0.03), and UVM (P<0.001) (Fig 3F–3J and S2J-S2O Fig in S1 File). For DFI (Fig 3K–3O and S2P-S2R Fig in S1 File), high RRM2 expression was linked to poor prognosis for cancers of KIRP (P = 0.007), LIHC (P = 0.038), LUAD (P = 0.005), PAAD (P = 0.022), SARC (P<0.001), TGCT (P = 0.043) and THCA (P = 0.001). Additionally, low RRM2 expression was associated with poor DFI for OV (P = 0.022). For PFI analysis data (Fig 3P–3T and S2A, S2B Fig in S1 File), high RRM2 expression was correlated with poor prognosis for ACC (P = 0.002), KICH (P = 0.007), KIRC (P = 0.025), KIRP (P<0.001), LGG (P = 0.001), LIHC (P = 0.003), LUAD (P = 0.003), MESO (P<0.001), PAAD (P = 0.002), PRAD (P<0.001), SARC (P = 0.001), THCA (P = 0.011), and UVM (P<0.001). However, low RRM2 expression was associated with poor PFI in COAD (P = 0.049) and STAD (P = 0.05).

Furthermore, we calculated survival data using Cox regression models (Fig 3U–3X). The OS, DSS, and PFI results were similar to those calculated using the Kaplan–Meier method. The difference in OS was that high RRM2 expression was not significantly correlated with poor prognosis in UCEC. Additionally, high RRM2 expression was associated with poor DSS in patients with SARC (P = 0.024). For PFI, high RRM2 expression was significantly correlated with poor prognosis for PCPG (P = 0.006) but was not significantly correlated with poor prognosis for STAD. For DFI, the data indicated that the high RRM2 expression was associated with the poor prognosis for cancers that included BRCA (P = 0.036), KIRP (P<0.001), LIHC (P = 0.021), LUAD (P<0.001), PAAD (P = 0.012), PRAD (P = 0.020), SARC (P = 0.002), and THCA (P<0.001). These data suggest that RRM2 is differentially associated with the prognosis of various cancers.

4. Genetic alteration analysis data

Next, we explored the genetic alteration status of RRM2 in 10,953 patients/10,967 samples from 32 TGCA cohort studies. The analysis data revealed that RRM2 exhibited the highest alteration frequency (>7%) in patients with uterine carcinosarcoma, among which "amplification" was the main type. Notably, the genomic alteration types in all diffuse large B-cell lymphoma (DLBCL) and KICH cases were deep deletions in RRM2 (Fig 4A). We investigated the types, sites, and numbers of RRM2 mutations (Fig 4B). The primary genetic mutation in RRM2 was a missense mutation. The R298Q/W mutation in ribonucleotide reductase that was detected in three cases of UCEC and one case of GBM was able to produce a missense mutation in the RRM2 gene, thus causing translation from R (arginine) to W (tryptophan) or glutamine (Q) at position 298 of the RRM2 protein. We visualized the R298 site in the 3D structure of RRM2 (Fig 4C).

Fig 4 — (A, B) The alteration frequency of *RRM2* with mutation type and mutation site. (C) The mutation site with the highest alteration frequency (R298Q/W) in the 3D structure of *RRM2*. (D) A radar map was used to reflect the correlation between *RRM2* expression and TMB. (E) A radar map was used to reflect the correlation between *RRM2* expression and MSI. TMB, Tumor mutational burden; MSI, Microsatellite instability.

Moreover, we explored the correlation between RRM2 expression and tumor mutational burden (TMB) and microsatellite instability (MSI) in all TCGA cancers. As presented in Fig 4D, RRM2 expression was positively correlated with TMB in ACC, BLCA, BRCA, CESC, CHOL, COAD, KICH, KIRC, LGG, LIHC, LUAD, LUSC, MESO, OV, PAAD, PRAD, READ, SARC, SKCM, and STAD but negatively correlated with THYM. As presented in Fig 4E, we observed a positive correlation between RRM2 expression and MSI for COAD, LIHC, SARC, STAD, TGCT, UCEC, and UCS (Uterine Carcinosarcoma) but a negative correlation for LAML and SKCM. These results should be subjected to more in-depth analysis.

5. Immune infiltration

Immune cells, the primary components of the tumor microenvironment (TME), are involved in the progression and metastasis of tumors and therapy resistance [23, 27]. Tumor-associated endothelial cells have been reported to play a key role in sculpting the immune responses necessary for tumor growth and metastasis [28]. First, we explored the association between RRM2 expression and the infiltration level of immune cells in TCGA cancers using the TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, XCELL, MCPCOUNTER, and EPIC algorithms. As presented in Fig 5A, RRM2 expression levels in BRCA, KIRC, LUAD, LUSC, STAD, THCA, and THYM were negatively correlated with the infiltration level of tumor-associated endothelial cells but were positively correlated with KIRP and LGG. We then analyzed the correlation between RRM2 expression levels and the immune infiltration of different tumor-associated cells (B cells, plasma cells, T cells, NK cells, monocytes, macrophages, dendritic cells, mast cells, eosinophils, and neutrophils) and their subtypes in tumors. The results indicated that RRM2 expression levels were significantly correlated with the immune infiltration of various tumor-associated cells in 24 tumor types. For example, RRM2 expression in the ACC was negatively correlated with the infiltration of resting mast cells (Fig 5B). In BLCA, RRM2 expression significantly correlated with the infiltration of five types of immune cells (Fig 5C–5G). In BRCA, RRM2 expression was significantly correlated with the infiltration of 10 types of immune cells (Fig 5H–5Q). The correlation between RRM2 expression and immune cell infiltration in other cancers is presented in S3A-S3CI Fig in S1 File.

Fig 5 — (A) The correlation between *RRM2* gene expression and the infiltration level of endothelial cells in all types of cancer in TCGA. (B-Q) The correlation between *RRM2* gene expression and the infiltration level of diverse immune cells in ACC, BLCA, and BRCA, respectively.

6. Immune checkpoint analysis

We explored the correlation between RRM2 and immune checkpoint gene expression in various cancers (Fig 6). The results revealed that the expression levels of more than 40 immune checkpoint genes were significantly associated with RRM2 expression levels in TGCT and THCA. Moreover, the expression levels of up to 30 immune checkpoint genes in BRCA, HNSC, KIRC, KIRP, LGG, LIHC, PRAD, THYM, and UVM correlated with RRM2 expression levels. Additionally, more than 20 immune checkpoint genes were associated with RRM2 expression in 10 cancer types.

7. Enrichment analysis of RRM2-related gene

To understand the molecular mechanism of action of RRM2 in the context of tumorigenesis, we searched for RRM2 expression-correlated target genes and RRM2-binding proteins for functional enrichment analysis. We identified 50 RRM2-binding proteins that were authenticated using STRING. The protein-protein interaction network is presented in Fig 7A. We then explored the top 100 RRM2 expression-correlated genes based on the TGCA datasets using GEPIA2. The results indicated that the expression level of RRM2 was positively associated with that of MKI67 (marker of proliferation Ki-67) (R = 0.79), ORC1 (origin recognition complex subunit 1) (R = 0.78), CCNA2 (Cyclin A2) (R = 0.77), PLK1 (polo-like kinase 1) (R = 0.77), and KIF11 (kinesin family member 11) (R = 0.76) (Fig 7B). The heatmap indicated a positive correlation between RRM2 and the four genes in virtually all cancer types (Fig 7C). The above two groups possessed four common genes that included PLK1, CDK1 (cyclin-dependent kinase 1), DTL (Denticleless E3 ubiquitin protein ligase homolog), and ASF1B (anti-silencing function 1 B histone chaperone) (Fig 7D). KEGG enrichment analyses were performed based on the genes in the two groups. The result indicated that “cell cycle” may play a crucial role in the effect of RRM2 on tumor pathogenesis (Fig 7E).

Fig 7 — (A) Protein-protein interaction network of the available experimentally determined RRM2 binding proteins. The size and color of the node depends on the degree. The width of the edge is determined by the combined score of STRING. (B) The expression correlation between *RRM2* and the top 5 *RRM2*-correlated genes in TCGA, including MKI67, ORC1, CCNA2, PLK1 and KIF11. (C) The corresponding heatmap data for the detailed cancer types. (D) An intersection analysis of the *RRM2*-binding and correlated genes. (E) KEGG pathway enrichment analyses of the genes that *RRM2*-binding and interacted.

8. Potential drug prediction for pan-cancer

We performed a gene set enrichment analysis (GSEA) to explore the pathways regulated by RRM2 in pan-cancer cells (S4 Fig in S1 File). The results revealed that the cell cycle pathway was the most significantly affected by RRM2 expression in pan-cancer, and this was consistent with the KEGG enrichment analyses (S1 Table in S1 File). Drug prediction analysis indicated that up to 14 approved drugs such as Phenylbutyrate and Romidepsin may exert pan-cancer therapeutic effects by targeting cell cycle-associated pathways (S2 Table in S1 File).

Discussion

Consistent with the extremely important biological functions of RRM2 in DNA replication [29], RRM2 has been demonstrated to exhibit a functional link with diverse tumors [7–9]. Whether RRM2 is involved in the pathogenesis of multiple tumors via a common molecular mechanism remains unclear. Through bibliography retrieval, we failed to identify any publication with a pan-cancer analysis of RRM2 based on the perspective of all tumors. Therefore, in this study, we uncovered for the first time the role of RRM2 in 33 different cancers. Using bioinformatic analysis of the Oncomine and TCGA public databases, we demonstrated that the expression of RRM2 in up to 19 tumor tissues was higher than that in the corresponding normal tissues. These findings demonstrated that RRM2 plays an important role in most tumors (Fig 1). Subsequently, the significance of RRM2 in pan-cancer clinical prognosis was explored. The expression of RRM2 was significantly related to age, race, tumor stage, and status in nearly one-third of the TGCA (Fig 2). Additionally, survival analyses using Kaplan–Meier and Cox regression models revealed that most patients with cancer and high RRM2 expression exhibited significantly worse survival rates than those with low expression (Fig 3). Considering the patient samples in the cBioPortal database, RRM2 gene mutations appeared in 23 types of patients with tumors, with an alteration frequency of 0.2% to 7.02%. We observed that most alterations in RRM2 were gene mutations, amplifications, and deep deletions (Fig 4). We also observed evidence of a close association between RRM2 expression and TMB or MSI in TCGA samples. These results demonstrate that RRM2 may be a powerful prognostic biomarker in pan-cancer and may expedite the development of precise targeted therapies for tumors.

RRM2 is highly expressed in the majority of tumors. However, given the limitations of online databases and tools, the expression of RRM2 in certain tumors was omitted. We supplemented missing meaningful results with a literature search. Tabbal et al. demonstrated that high expression of RRM2 induced by EZH2 is associated with poor prognosis in adrenocortical carcinoma (ACC) [30]. Inhibition of RRM2 can block cell proliferation and migration and induce apoptosis, thus suggesting that RRM2 may be a target in ACC [30]. Aimiuwu et al. demonstrated that 5-Azacytidine (5-azaC) could cause perturbation of deoxyribonucleotide pools (LAML) and that RRM2 may be a novel molecular target of 5-azaC in AML [31]. In Mesothelioma, Wendy et al. reported that RRM2 was highly expressed in MESO by semi-quantitative immunohistochemical analysis in 70 patients, but no significant correlation was observed between RRM2 expression and the clinical prognosis of OS and PFS [32]. The current data revealed a strong relationship between RRM2 and up to 20 types of tumors; however, further research is required to explore if RRM2 is related to the remaining tumors. Consistent with this result, our clinical data correlation analysis indicated that RRM2 was strongly correlated with age, race, tumor stage, and cancer status. These results indicate that RRM2 plays an important pan-cancer role and possesses clinical value that is worthy of in-depth investigation.

Cox regression models and the Kaplan–Meier method were used to evaluate the survival of patients with RRM2 tumors. However, for certain tumors, the results of the two algorithms were inconsistent. In this study, we used Cox regression survival analysis of data from the TCGA-UCEC cohort and observed a statistical correlation between high RRM2 expression and poor OS (P = 0.021). Nevertheless, no significant correlation was observed between RRM2 expression and OS in UCEC using the Kaplan–Meier method (P = 0.133). Different data-processing methods or updated survival data may have contributed to these results. Therefore, we used another web tool, GEPIA2 [33], and failed to detect a correlation between RRM2 expression and overall survival (years) of patients with UCEC (P = 0.064). Consequently, the current evidence cannot confirm the role of RRM2 expression in the OS of UCEC. For other tumors with identical DFI, DSS, and PFI results, larger sample sizes and clinical studies are needed to further confirm the relationship between RRM2 and the survival prognosis of different tumors, and this indicates the complexity of tumors and the diverse roles of RRM2.

For pancreatic adenocarcinoma (PAAD), we analyzed the TCGA-PAAD dataset (n = 183) and failed to observe significant differential expression of RRM2 in PAAD tissues compared to levels in normal tissues. However, a significant correlation was observed between RRM2 expression and the clinical prognoses of OS, PFS, RFS, and DSS in patients with PAAD. A recent study by Anna et al. was in agreement with the results of the survival analysis [34]. Therefore, larger sample sizes are required to confirm the role of RRM2 in PAAD.

In this study, we demonstrated that pan-cancer RRM2 expression levels correlated with the immune infiltration levels of diverse tumor-associated cells (Fig 5). High RRM2 expression leads to decreased immune infiltration in most cancers, including ACC, KIRC, KIRP, LGG, LIHC, LUAD, PAAD, PRAD, SARC, TGCT, THCA, UCEC, and UVM. Consistent with this finding, high RRM2 expression was associated with poor prognosis in these tumors. These findings indicate that in at least 13 types of tumors, RRM2 can affect tumor prognosis by regulating the level of immune infiltration.

Immune checkpoint blockade has exhibited remarkable advantages in the treatment of several cancer types [35]. Immune checkpoint blockade increases anti-tumor immunity [35]. Here, we demonstrate that RRM2 expression is closely related to immune checkpoint genes in various cancers (Fig 6). In renal cell carcinoma, Xiong et al. reported that RRM2 promotes sunitinib resistance and that knockdown of RRM2 enhances the anti-tumor efficiency of programmed cell death protein 1 (PD-1) blockade in renal cancer [36]. Our data analysis also revealed that the expression of RRM2 was related to 21, 38, and 30 checkpoint genes in KICH, KIRC, and KIRP cells, respectively. Additionally, we confirmed that the expression of RRM2 is positively associated with PDCD1 (PD-1) in KICH, KIRC, and KIRP. These results suggested that RRM2 is a promising therapeutic target for renal cell carcinoma. Nevertheless, the specific immunotherapeutic role of RRM2 in immune checkpoint blockade requires further pan-cancer studies.

First, we integrated the data for RRM2-binding components and RRM2 expression-correlated target genes across all tumors (Fig 7). KEGG and KSEA enrichment analyses indicated that “cell cycle,” “oocyte meiosis,” “p53 signaling pathway,” “cell senescence,” and “DNA replication” play potential roles in the effect of RRM2 on tumor pathogenesis. One research indicates that cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer [37]. Chao Ma et. al displayed RRM2 was an independent prognostic factor in lung adenocarcinoma which was closely related oocyte meiosis [38]. Mingxue Yu et. al found that RRM2 were enriched in the p53 signaling pathway and could be potential biomarkers and therapeutic targets for HBV-related HCC [39]. Letizia Granieri et. al revealed that targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors [40]. Wenxiu Qi et. al suggested that VE-822 and AZD1775 decreased the protein levels of ribonucleotide reductase M1 (RRM1) and M2 (RRM2) subunits, key enzymes in the synthesis of deoxyribonucleoside triphosphate, which increased DNA replication stress [41].

Given the importance of RRM2 in tumors, we explored drugs that target RRM2. We identified drugs that target the cell cycle pathway most affected by RRM2 expression in pan-cancers. Nevertheless, whether these drugs play a role in the treatment of cancer or certain tumors must be further explored. RRM2 converts the active metabolite of gemcitabine into its inactive form [42]. Moreover, alterations in RRM2 are associated with resistance to gemcitabine-induced cell death in lung cancer and pancreatic ductal adenocarcinoma [42]. Therefore, we speculated that some of these predicted drugs could regulate the efficacy of gemcitabine in certain cancers. Further research is required to confirm these findings.

In summary, our first pan-cancer analysis of RRM2 revealed statistical correlations between RRM2 expression and clinical prognosis, genetic alterations, tumor mutational burden, microsatellite instability, immune cell infiltration, and immune checkpoints across multiple tumors. This helped us to understand the role of RRM2 in tumorigenesis from the perspective of clinical tumor samples.

Supporting information

S1 File. Contains all data for S1–S4 Figs and S1, S2 Tables.

(DOCX)

pone.0299949.s001.docx^{(1.1MB, docx)}

Acknowledgments

Special thanks to Yong Wang for performing the data analysis. We are also grateful for the data collection by Jing Zhang. All authors contributed equally to data analysis, experiments, and overall manuscript conception.

This work has been uploaded in a preprint. We thank Research Square for presenting and evaluating our study (https://www.researchsquare.com/article/rs-2215057/v1).

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by the Jiangsu Provincial Special Program of Medical Science (BE2019750), National Natural Science Foundation of China (81827805), National Key Research and Development Program (2018YFA0704100, 2018YFA0704104), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (61821002), and Interventional Radiology Scientific Research Special Fund Project of Jiangsu Medical Association (SYH-3201140-0025 (2021020)).

References

1.Morris LG, Chan TA. Therapeutic targeting of tumor suppressor genes. Cancer. 2015;121(9):1357–68. Epub 20141229. doi: 10.1002/cncr.29140 ; PubMed Central PMCID: PMC4526158. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Li ZX, Zheng ZQ, Wei ZH, Zhang LL, Li F, Lin L, et al. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019;9(25):7648–65. Epub 20191014. doi: 10.7150/thno.36585 ; PubMed Central PMCID: PMC6831462. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430–9. doi: 10.1053/j.seminoncol.2010.09.005 . [DOI] [PubMed] [Google Scholar]
4.Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–102. Epub 20091130. doi: 10.1038/onc.2009.416 . [DOI] [PubMed] [Google Scholar]
5.Kumar D, Abdulovic AL, Viberg J, Nilsson AK, Kunkel TA, Chabes A. Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools. Nucleic Acids Res. 2011;39(4):1360–71. Epub 20101020. doi: 10.1093/nar/gkq829 ; PubMed Central PMCID: PMC3045583. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Gandhi M, Groß M, Holler JM, Coggins SA, Patil N, Leupold JH, et al. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1—RRM2 axis in cancer. Nat Commun. 2020;11(1):3214. Epub 20200625. doi: 10.1038/s41467-020-17007-9 ; PubMed Central PMCID: PMC7316977. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, et al. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019;25(14):4480–92. Epub 20190417. doi: 10.1158/1078-0432.CCR-18-4046 ; PubMed Central PMCID: PMC6820162. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Zheng S, Wang X, Weng YH, Jin X, Ji JL, Guo L, et al. siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. Mol Ther Nucleic Acids. 2018;12:805–16. Epub 20180808. doi: 10.1016/j.omtn.2018.08.003 ; PubMed Central PMCID: PMC6118156. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20(1):97. Epub 20210727. doi: 10.1186/s12943-021-01393-9 ; PubMed Central PMCID: PMC8314608. [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Yang Y, Lin J, Guo S, Xue X, Wang Y, Qiu S, et al. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer. Cancer Cell Int. 2020;20(1):587. Epub 20201207. doi: 10.1186/s12935-020-01689-8 ; PubMed Central PMCID: PMC7720568. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Sun H, Yang B, Zhang H, Song J, Zhang Y, Xing J, et al. RRM2 is a potential prognostic biomarker with functional significance in glioma. Int J Biol Sci. 2019;15(3):533–43. Epub 20190101. doi: 10.7150/ijbs.30114 ; PubMed Central PMCID: PMC6367584. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2020;13(3):3518–35. Epub 20201219. doi: 10.18632/aging.202292 ; PubMed Central PMCID: PMC7906179. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, et al. Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res. 2016;14(9):767–75. Epub 20160613. doi: 10.1158/1541-7786.MCR-16-0099 ; PubMed Central PMCID: PMC5025362. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Huang N, Guo W, Ren K, Li W, Jiang Y, Sun J, et al. LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2. Front Oncol. 2019;9:1103. Epub 20191022. doi: 10.3389/fonc.2019.01103 ; PubMed Central PMCID: PMC6817562. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Rasmussen RD, Gajjar MK, Tuckova L, Jensen KE, Maya-Mendoza A, Holst CB, et al. BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun. 2016;7:13398. Epub 20161115. doi: 10.1038/ncomms13398 ; PubMed Central PMCID: PMC5116074. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Goss KL, Koppenhafer SL, Waters T, Terry WW, Wen KK, Wu M, et al. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene. 2021;40(3):564–77. Epub 20201115. doi: 10.1038/s41388-020-01552-0 ; PubMed Central PMCID: PMC7856031. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Chen CW, Li Y, Hu S, Zhou W, Meng Y, Li Z, et al. DHS (trans-4,4’-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2). Oncogene. 2019;38(13):2364–79. Epub 20181205. doi: 10.1038/s41388-018-0584-6 ; PubMed Central PMCID: PMC6705423. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8. doi: 10.1038/s41587-020-0546-8 ; PubMed Central PMCID: PMC7386072. [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. Epub 20150120. doi: 10.1093/nar/gkv007 ; PubMed Central PMCID: PMC4402510. [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. Epub 20170419. doi: 10.1186/s13073-017-0424-2 ; PubMed Central PMCID: PMC5395719. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342–50. Epub 20161003. doi: 10.1038/nm.4191 . [DOI] [PubMed] [Google Scholar]
22.Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w14. doi: 10.1093/nar/gkaa407 ; PubMed Central PMCID: PMC7319575. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front Immunol. 2020;11:784. Epub 20200507. doi: 10.3389/fimmu.2020.00784 ; PubMed Central PMCID: PMC7221158. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504. doi: 10.1101/gr.1239303 ; PubMed Central PMCID: PMC403769. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15(1):293. Epub 20140829. doi: 10.1186/1471-2105-15-293 ; PubMed Central PMCID: PMC4261873. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48(D1):D1031–d41. doi: 10.1093/nar/gkz981 ; PubMed Central PMCID: PMC7145558. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019;7(1):224. Epub 20190822. doi: 10.1186/s40425-019-0667-0 ; PubMed Central PMCID: PMC6704558. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.De Sanctis F, Ugel S, Facciponte J, Facciabene A. The dark side of tumor-associated endothelial cells. Semin Immunol. 2018;35:35–47. Epub 20180226. doi: 10.1016/j.smim.2018.02.002 . [DOI] [PubMed] [Google Scholar]
29.Shu Z, Li Z, Huang H, Chen Y, Fan J, Yu L, et al. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition. Oncogene. 2020;39(35):5721–33. Epub 20200725. doi: 10.1038/s41388-020-01403-y . [DOI] [PubMed] [Google Scholar]
30.Tabbal H, Septier A, Mathieu M, Drelon C, Rodriguez S, Djari C, et al. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. Br J Cancer. 2019;121(5):384–94. Epub 20190731. doi: 10.1038/s41416-019-0538-y ; PubMed Central PMCID: PMC6738105. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012;119(22):5229–38. Epub 20120419. doi: 10.1182/blood-2011-11-382226 ; PubMed Central PMCID: PMC3369613. [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Muñoz-Montaño W, Muñiz-Hernández S, Avilés-Salas A, Catalán R, Lara-Mejía L, Samtani-Bassarmal S, et al. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer. 2021;21(1):892. Epub 20210805. doi: 10.1186/s12885-021-08287-5 ; PubMed Central PMCID: PMC8340445. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w60. doi: 10.1093/nar/gkz430 ; PubMed Central PMCID: PMC6602440. [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Klimaszewska-Wiśniewska A, Buchholz K, Neska-Długosz I, Durślewicz J, Grzanka D, Zabrzyński J, et al. Expression of Genomic Instability-Related Molecules: Cyclin F, RRM2 and SPDL1 and Their Prognostic Significance in Pancreatic Adenocarcinoma. Cancers (Basel). 2021;13(4). Epub 20210218. doi: 10.3390/cancers13040859 ; PubMed Central PMCID: PMC7922901. [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158–68. doi: 10.1056/NEJMra1703481 . [DOI] [PubMed] [Google Scholar]
36.Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh). 2021;8(18):e2100881. Epub 20210728. doi: 10.1002/advs.202100881 ; PubMed Central PMCID: PMC8456228. [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Grolmusz VK, Karászi K, Micsik T, Tóth EA, Mészáros K, Karvaly G, et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J Cancer Res. 2016;6(9):2041–53. Epub 20160901. ; PubMed Central PMCID: PMC5043113. [PMC free article] [PubMed] [Google Scholar]
38.Ma C, Luo H, Cao J, Gao C, Fa X, Wang G. Independent prognostic implications of RRM2 in lung adenocarcinoma. J Cancer. 2020;11(23):7009–22. Epub 20201017. doi: 10.7150/jca.47895 ; PubMed Central PMCID: PMC7592001. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Yu M, Xu W, Jie Y, Pang J, Huang S, Cao J, et al. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma. World J Surg Oncol. 2021;19(1):66. Epub 20210308. doi: 10.1186/s12957-021-02174-w ; PubMed Central PMCID: PMC7938465. [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A, et al. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell Rep. 2022;40(12):111396. doi: 10.1016/j.celrep.2022.111396 . [DOI] [PubMed] [Google Scholar]
41.Qi W, Xu X, Wang M, Li X, Wang C, Sun L, et al. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochem Pharmacol. 2019;164:273–82. Epub 20190420. doi: 10.1016/j.bcp.2019.04.022 . [DOI] [PubMed] [Google Scholar]
42.Daylami R, Muilenburg DJ, Virudachalam S, Bold RJ. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res. 2014;33(1):102. Epub 20141212. doi: 10.1186/s13046-014-0102-9 ; PubMed Central PMCID: PMC4279680. [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0299949.r001

Decision Letter 0

Arthur J Lustig

18 Jan 2024

PONE-D-23-34369A Comprehensive Analysis of Ribonucleotide Reductase Subunit M2 to Carcinogenesis in Pan-CancerPLOS ONE

Dear Dr. Zeng,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The ability to peer-review a paper is dependent on the clarity of writing. In this regard, two issues must be dealt with before resubmission and re-review. In this regard, the manuscript requires a major improvement in English writing style and in clarity with respect to specific ideas as indicated by Reviewer 1.

2, While the issue of novelty pointed out by Reviewer 2 is not relevant for this journal, the authors should nonetheless identify which of the findings add to our current knowledge in the field.

Please submit your revised manuscript by Mar 03 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Arthur J. Lustig, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“This work was supported by the Jiangsu Provincial Special Program of Medical Science (BE2019750), National Natural Science Foundation of China (81827805), National Key Research and Development Program (2018YFA0704100, 2018YFA0704104), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (61821002), and Interventional Radiology Scientific Research Special Fund Project of Jiangsu Medical Association (SYH-3201140-0025 (2021020)).”

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study addressed the role of RRM2 in various tumors, which provide some interesting information for understanding carcinogenesis. There are some flaws needed to be addressed, as followings.

1- English should be carefully revised throughout the manuscript.

2- The quality of figures is very poor, and should be improved.

3- Introduction, page 3, line 22: “…to perform pan-cancer analysis of genes…” should be “…to perform a pan-cancer analysis of genes…”

4- Description of RRM2 gene expression should be in Italic and consistent through the manuscript.

5- Material and methods, page 4, line 78: “we chose…” should be “We chose…”

6- Material and methods, page 4, line 79: “…immune infiltrates of endothelial cell…” should be “…immune infiltrates of endothelial cells…”

7- Material and methods, page 5, line 97: “[24)” should be “[24]”

8- Material and methods, page 5, line 97: “pan-cencer” should be “pan-cancer”

9- Material and methods, page 4, “Genetic alteration analysis section”: In the analysis of RRM2 gene mutations, it is better to provide the accession number of RRM2 coding sequence used for the analysis.

10- Results, page 6, “RRM2 expression and clinical correlation in pan-cancer”: The authors examined the correlation between RRM2 expression and clinical characteristics of cancer patients, and found that RRM2 expression was significantly related to age, race, tumor stage, and status of cancer patients. It is better to describe in the main text, which age, race and tumor stage are associated with high RRM2 expression level.

11- Results, page 6, line 143-144: “…tumor patients’ clinical characteristics of patients with pan-cancer…” should be “…tumor clinical characteristics of patients with pan-cancer…”

12- Results, page 9, line 218: “…tumor mutational burden) TMB)…” should be “…tumor mutational burden (TMB)…”

13- Results, page 10, line 273: “…in Fig 7A We the…” should be “…in Fig 7A. We the…”

14- Discussion, page 13, lines 376-379: the authors found that “cell cycle”, “p53 signaling pathway”, “cell senescence, and other cellular pathways have potential roles in the effect of RRM2 on carcinogenesis. It is better to discuss these results according to the literature data.

Reviewer #2: Numerous experimental studies have been conducted to show that RRM2 is associated with the occurrence and development of tumors. And the function and mechanism of RRM2 in tumors has also been relatively well studied. Therefore, this manuscript lacks novelty.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Apr 18;19(4):e0299949. doi: 10.1371/journal.pone.0299949.r002

Author response to Decision Letter 0

29 Jan 2024

Response to Reviewers

Reviewer #1: This study addressed the role of RRM2 in various tumors, which provide some interesting

information for understanding carcinogenesis. There are some flaws needed to be addressed, as followings.

1-English should be carefully revised throughout the manuscript.

A: I've done a native polish on the entire manuscript by Elsevier professional language polishing services.

2-The quality of figures is very poor, and should be improved.

A: All the figures have been improved.

3-Introduction, page 3, line 22: “…to perform pan-cancer analysis of genes…” should be “…to perform a pan-cancer analysis of genes…”

A: “…to perform pan-cancer analysis of genes…” has been modified into “…to perform pan-cancer analyses of genes…”according to Elsevier professional language polishing services.

4-Description of RRM2 gene expression should be in Italic and consistent through the manuscript.

A: All description of RRM2 gene expression have be revised in Italic and consistent through the manuscript.

5-Material and methods, page 4, line 78: “we chose…” should be “We chose…”

A: “we chose…” has been modified into “We chose…”

6-Material and methods, page 4, line 79: “…immune infiltrates of endothelial cell…” should be “…immune infiltrates of endothelial cells…”

A: …immune infiltrates of endothelial cell…” has been modified into “…immune infiltrates of endothelial cells…”

7-Material and methods, page 5, line 97: “[24)” should be “[24]”

A: “[24)” has been modified into “[24]”

8-Material and methods, page 5, line 97: “pan-cencer” should be “pan-cancer”

A: “pan-cencer” has been modified into “pan-cancer”

9-Material and methods, page 4, “Genetic alteration analysis section”: In the analysis of RRM2 gene mutations, it is better to provide the accession number of RRM2 coding sequence used for the analysis.

A: The number of RRM2 coding sequence is NC_000002.12NC_000002.12

10-Results, page 6, “RRM2 expression and clinical correlation in pan-cancer”: The authors examined the correlation between RRM2 expression and clinical characteristics of cancer patients, and found that RRM2 expression was significantly related to age, race, tumor stage, and status of cancer patients. It is better to describe in the main text, which age, race and tumor stage are associated with high RRM2 expression level.

A: The clinical characteristics of patients have been described in the main text, which age, race and tumor stage are associated with high RRM2 expression level.

11-Results, page 6, line 143-144: “…tumor patients’ clinical characteristics of patients with pan-cancer…” should be “…tumor clinical characteristics of patients with pan-cancer…”

A: “…tumor patients’ clinical characteristics of patients with pan-cancer…”have been modified into “…the clinical characteristics of patients with pan-cancer…”according to Elsevier professional language polishing services.

12-Results, page 9, line 218: “…tumor mutational burden) TMB) …” should be “…tumor mutational burden (TMB)…”

A: “…tumor mutational burden) TMB)…” has been modified into “…tumor mutational burden(TMB)…”

13-Results, page 10, line 273: “…in Fig 7A We the…” should be “…in Fig 7A. We the…”

A: “…in Fig 7A We the…” has been modified into “…in Fig 7A. We the…”

14-Discussion, page 13, lines 376-379: the authors found that “cell cycle”, “p53 signaling pathway”, “cell senescence, and other cellular pathways have potential roles in the effect of RRM2 on carcinogenesis. It is better to discuss these results according to the literature data.

A: The “cell cycle”, “p53 signaling pathway”, “cell senescence, and other cellular pathways have potential roles in the effect of RRM2 on carcinogenesis. I discussed these results according to the literature data.

Reviewer #2: Numerous experimental studies have been conducted to show that RRM2 is associated

with the occurrence and development of tumors. And the function and mechanism of RRM2 in

tumors have also been relatively well studied. Therefore, this manuscript lacks novelty.

A: Indeed, many studies have reported the close relationship between RRM2 and tumorigenesis and development, but most of them still focus on tumor invasion and proliferation and corresponding signaling pathways and other tumor molecular mechanisms. In this paper, we have made a relatively new interpretation of the mechanism of RRM2 regulation of tumor from the perspective of the immune mechanism of RRM2 and tumor-infiltrating lymphocytes and immune checkpoint molecules, which may provide certain theoretical support for tumor immunotherapy.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0299949.s002.docx^{(16.6KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0299949.r003

Decision Letter 1

Arthur J Lustig

14 Feb 2024

PONE-D-23-34369R1A Comprehensive Analysis of Ribonucleotide Reductase Subunit M2 for Carcinogenesis in Pan-CancerPLOS ONE

Dear Dr. Zeng,

Specifically, respond to Reviewer 2 with regard to a clarification on the rationale for the enrichment analysis of SND1-related partners. However you can ignore the comments about the resolution issues since the downloaded figures are sufficiently resolved. Please submit your revised manuscript by Mar 30 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

We look forward to receiving your revised manuscript.

Kind regards,

Arthur J. Lustig, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: Authors addressed the comments raised by this reviewer and this paper seems to be now ready for publication.

Reviewer #2: 1. Why did "Enrichment analysis of SND1-related partners"? Is there a relationship of RRM2 and SND1?

2. Please consider to cite "" ext-link-type="uri" xlink:type="simple">https://doi.org/10.1016/j.gendis.2022.11.022".

3. All figures have to be uploaded in high resolution.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

PLoS One. 2024 Apr 18;19(4):e0299949. doi: 10.1371/journal.pone.0299949.r004

Author response to Decision Letter 1

17 Feb 2024

Reviewer #2:

1. Why did "Enrichment analysis of SND1-related partners"? Is there a relationship of RRM2 and SND1?

A: I'm very sorry. Thank you for your careful review. This is actually a clerical error on my part. It's actually “Enrichment analysis of RRM2-related gene”. I have already corrected all the relevant clerical errors in the Methods and Results.

2. Please consider to cite "https://doi.org/10.1016/j.gendis.2022.11.022".

A: Sorry, I don't know what this link means and where to reference it. Besides, this link is typed to show AN ERROR with DOI NOT FOUND.

3. All figures have to be uploaded in high resolution.

A: All figures have been uploaded in high resolution

Attachment

Submitted filename: Response to Reviewers.docx

pone.0299949.s003.docx^{(14.2KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0299949.r005

Decision Letter 2

Arthur J Lustig

21 Feb 2024

A Comprehensive Analysis of Ribonucleotide Reductase Subunit M2 for Carcinogenesis in Pan-Cancer

PONE-D-23-34369R2

Dear Dr. Zeng,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Arthur J. Lustig, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

PLoS One. doi: 10.1371/journal.pone.0299949.r006

Acceptance letter

Arthur J Lustig

21 Mar 2024

PONE-D-23-34369R2

PLOS ONE

Dear Dr. Zeng,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Arthur J. Lustig

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 File. Contains all data for S1–S4 Figs and S1, S2 Tables.

(DOCX)

pone.0299949.s001.docx^{(1.1MB, docx)}

Attachment

Submitted filename: Response to Reviewers.docx

pone.0299949.s002.docx^{(16.6KB, docx)}

Attachment

Submitted filename: Response to Reviewers.docx

pone.0299949.s003.docx^{(14.2KB, docx)}

Data Availability Statement

All relevant data are within the paper and its Supporting Information files.

[pone.0299949.ref001] 1.Morris LG, Chan TA. Therapeutic targeting of tumor suppressor genes. Cancer. 2015;121(9):1357–68. Epub 20141229. doi: 10.1002/cncr.29140 ; PubMed Central PMCID: PMC4526158. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref002] 2.Li ZX, Zheng ZQ, Wei ZH, Zhang LL, Li F, Lin L, et al. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019;9(25):7648–65. Epub 20191014. doi: 10.7150/thno.36585 ; PubMed Central PMCID: PMC6831462. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref003] 3.Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430–9. doi: 10.1053/j.seminoncol.2010.09.005 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref004] 4.Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–102. Epub 20091130. doi: 10.1038/onc.2009.416 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref005] 5.Kumar D, Abdulovic AL, Viberg J, Nilsson AK, Kunkel TA, Chabes A. Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools. Nucleic Acids Res. 2011;39(4):1360–71. Epub 20101020. doi: 10.1093/nar/gkq829 ; PubMed Central PMCID: PMC3045583. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref006] 6.Gandhi M, Groß M, Holler JM, Coggins SA, Patil N, Leupold JH, et al. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1—RRM2 axis in cancer. Nat Commun. 2020;11(1):3214. Epub 20200625. doi: 10.1038/s41467-020-17007-9 ; PubMed Central PMCID: PMC7316977. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref007] 7.Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, et al. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019;25(14):4480–92. Epub 20190417. doi: 10.1158/1078-0432.CCR-18-4046 ; PubMed Central PMCID: PMC6820162. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref008] 8.Zheng S, Wang X, Weng YH, Jin X, Ji JL, Guo L, et al. siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. Mol Ther Nucleic Acids. 2018;12:805–16. Epub 20180808. doi: 10.1016/j.omtn.2018.08.003 ; PubMed Central PMCID: PMC6118156. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref009] 9.Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20(1):97. Epub 20210727. doi: 10.1186/s12943-021-01393-9 ; PubMed Central PMCID: PMC8314608. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref010] 10.Yang Y, Lin J, Guo S, Xue X, Wang Y, Qiu S, et al. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer. Cancer Cell Int. 2020;20(1):587. Epub 20201207. doi: 10.1186/s12935-020-01689-8 ; PubMed Central PMCID: PMC7720568. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref011] 11.Sun H, Yang B, Zhang H, Song J, Zhang Y, Xing J, et al. RRM2 is a potential prognostic biomarker with functional significance in glioma. Int J Biol Sci. 2019;15(3):533–43. Epub 20190101. doi: 10.7150/ijbs.30114 ; PubMed Central PMCID: PMC6367584. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref012] 12.Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2020;13(3):3518–35. Epub 20201219. doi: 10.18632/aging.202292 ; PubMed Central PMCID: PMC7906179. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref013] 13.Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, et al. Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res. 2016;14(9):767–75. Epub 20160613. doi: 10.1158/1541-7786.MCR-16-0099 ; PubMed Central PMCID: PMC5025362. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref014] 14.Huang N, Guo W, Ren K, Li W, Jiang Y, Sun J, et al. LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2. Front Oncol. 2019;9:1103. Epub 20191022. doi: 10.3389/fonc.2019.01103 ; PubMed Central PMCID: PMC6817562. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref015] 15.Rasmussen RD, Gajjar MK, Tuckova L, Jensen KE, Maya-Mendoza A, Holst CB, et al. BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun. 2016;7:13398. Epub 20161115. doi: 10.1038/ncomms13398 ; PubMed Central PMCID: PMC5116074. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref016] 16.Goss KL, Koppenhafer SL, Waters T, Terry WW, Wen KK, Wu M, et al. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene. 2021;40(3):564–77. Epub 20201115. doi: 10.1038/s41388-020-01552-0 ; PubMed Central PMCID: PMC7856031. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref017] 17.Chen CW, Li Y, Hu S, Zhou W, Meng Y, Li Z, et al. DHS (trans-4,4’-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2). Oncogene. 2019;38(13):2364–79. Epub 20181205. doi: 10.1038/s41388-018-0584-6 ; PubMed Central PMCID: PMC6705423. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref018] 18.Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8. doi: 10.1038/s41587-020-0546-8 ; PubMed Central PMCID: PMC7386072. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref019] 19.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. Epub 20150120. doi: 10.1093/nar/gkv007 ; PubMed Central PMCID: PMC4402510. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref020] 20.Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. Epub 20170419. doi: 10.1186/s13073-017-0424-2 ; PubMed Central PMCID: PMC5395719. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref021] 21.Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342–50. Epub 20161003. doi: 10.1038/nm.4191 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref022] 22.Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w14. doi: 10.1093/nar/gkaa407 ; PubMed Central PMCID: PMC7319575. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref023] 23.Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front Immunol. 2020;11:784. Epub 20200507. doi: 10.3389/fimmu.2020.00784 ; PubMed Central PMCID: PMC7221158. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref024] 24.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504. doi: 10.1101/gr.1239303 ; PubMed Central PMCID: PMC403769. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref025] 25.Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15(1):293. Epub 20140829. doi: 10.1186/1471-2105-15-293 ; PubMed Central PMCID: PMC4261873. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref026] 26.Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48(D1):D1031–d41. doi: 10.1093/nar/gkz981 ; PubMed Central PMCID: PMC7145558. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref027] 27.Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019;7(1):224. Epub 20190822. doi: 10.1186/s40425-019-0667-0 ; PubMed Central PMCID: PMC6704558. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref028] 28.De Sanctis F, Ugel S, Facciponte J, Facciabene A. The dark side of tumor-associated endothelial cells. Semin Immunol. 2018;35:35–47. Epub 20180226. doi: 10.1016/j.smim.2018.02.002 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref029] 29.Shu Z, Li Z, Huang H, Chen Y, Fan J, Yu L, et al. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition. Oncogene. 2020;39(35):5721–33. Epub 20200725. doi: 10.1038/s41388-020-01403-y . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref030] 30.Tabbal H, Septier A, Mathieu M, Drelon C, Rodriguez S, Djari C, et al. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. Br J Cancer. 2019;121(5):384–94. Epub 20190731. doi: 10.1038/s41416-019-0538-y ; PubMed Central PMCID: PMC6738105. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref031] 31.Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012;119(22):5229–38. Epub 20120419. doi: 10.1182/blood-2011-11-382226 ; PubMed Central PMCID: PMC3369613. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref032] 32.Muñoz-Montaño W, Muñiz-Hernández S, Avilés-Salas A, Catalán R, Lara-Mejía L, Samtani-Bassarmal S, et al. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer. 2021;21(1):892. Epub 20210805. doi: 10.1186/s12885-021-08287-5 ; PubMed Central PMCID: PMC8340445. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref033] 33.Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w60. doi: 10.1093/nar/gkz430 ; PubMed Central PMCID: PMC6602440. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref034] 34.Klimaszewska-Wiśniewska A, Buchholz K, Neska-Długosz I, Durślewicz J, Grzanka D, Zabrzyński J, et al. Expression of Genomic Instability-Related Molecules: Cyclin F, RRM2 and SPDL1 and Their Prognostic Significance in Pancreatic Adenocarcinoma. Cancers (Basel). 2021;13(4). Epub 20210218. doi: 10.3390/cancers13040859 ; PubMed Central PMCID: PMC7922901. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref035] 35.Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158–68. doi: 10.1056/NEJMra1703481 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref036] 36.Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh). 2021;8(18):e2100881. Epub 20210728. doi: 10.1002/advs.202100881 ; PubMed Central PMCID: PMC8456228. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref037] 37.Grolmusz VK, Karászi K, Micsik T, Tóth EA, Mészáros K, Karvaly G, et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J Cancer Res. 2016;6(9):2041–53. Epub 20160901. ; PubMed Central PMCID: PMC5043113. [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref038] 38.Ma C, Luo H, Cao J, Gao C, Fa X, Wang G. Independent prognostic implications of RRM2 in lung adenocarcinoma. J Cancer. 2020;11(23):7009–22. Epub 20201017. doi: 10.7150/jca.47895 ; PubMed Central PMCID: PMC7592001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref039] 39.Yu M, Xu W, Jie Y, Pang J, Huang S, Cao J, et al. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma. World J Surg Oncol. 2021;19(1):66. Epub 20210308. doi: 10.1186/s12957-021-02174-w ; PubMed Central PMCID: PMC7938465. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0299949.ref040] 40.Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A, et al. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell Rep. 2022;40(12):111396. doi: 10.1016/j.celrep.2022.111396 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref041] 41.Qi W, Xu X, Wang M, Li X, Wang C, Sun L, et al. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochem Pharmacol. 2019;164:273–82. Epub 20190420. doi: 10.1016/j.bcp.2019.04.022 . [DOI] [PubMed] [Google Scholar]

[pone.0299949.ref042] 42.Daylami R, Muilenburg DJ, Virudachalam S, Bold RJ. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res. 2014;33(1):102. Epub 20141212. doi: 10.1186/s13046-014-0102-9 ; PubMed Central PMCID: PMC4279680. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer

Yong Wang

Rong Chen

Jing Zhang

Peng Zeng

Roles

Abstract

Background

Methods

Results

Conclusions

Introduction

Materials and methods

1. The expression of RRM2 in pan-cancer

2. RRM2 expression and its clinical correlation in pan-cancer

3. Survival prognosis analysis and Cox regression models

4. Genetic alteration analysis

5. Immune infiltration analysis

6. Immune checkpoint analysis

7. Enrichment analysis of RRM2-related gene

8. Potential drug prediction for pan-cancer

Results

1. The expression of RRM2 in pan-cancer

Fig 1. The expression level of RRM2 in pan-cancer.

2. RRM2 expression and clinical correlation in pan-cancer

Fig 2. The expression level of RRM2 and its clinical correlation in pan-cancer.

3. Survival analysis

Fig 3. Prognostic value of RRM2 in pan-cancer.

4. Genetic alteration analysis data

Fig 4. Mutation features of RRM2 in different tumors of TCGA.

5. Immune infiltration

Fig 5. Correlation analysis between RRM2 expression and immune infiltration of cancer-associated cells.

6. Immune checkpoint analysis

Fig 6. RRM2 expression level and immune checkpoint genes in pan-cancer.

7. Enrichment analysis of RRM2-related gene

Fig 7. RRM2-related gene enrichment analysis.

8. Potential drug prediction for pan-cancer

Discussion

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Arthur J Lustig

Roles

Author response to Decision Letter 0

Decision Letter 1

Arthur J Lustig

Roles

Author response to Decision Letter 1

Decision Letter 2

Arthur J Lustig

Roles

Acceptance letter

Arthur J Lustig

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases